SAB Biotherapeutics Warrant
SABSW
6 hedge funds and large institutions have $21.1K invested in SAB Biotherapeutics Warrant in 2026 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 3 reducing their positions, and 2 closing their positions.
152% more capital invested
Capital invested by funds: $8.34K → $21.1K (+$12.7K)
14% less funds holding
Funds holding: 7 → 6 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LP
LMR Partners
London,
United Kingdom
|
+$18.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$69 |
| 2 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
-$33 |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$3 |
| 4 |
CS
Clear Street
New York
|
-$3 |
| 5 |
GS
GTS Securities
New York
|
-$3 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LP
1
LMR Partners
London,
United Kingdom
| $14.1K | +$18.6K | +539,588 | New |
|
2
Morgan Stanley
New York
| $3.71K | – | – | – |
|
|
CS
3
Clear Street
New York
| $2.06K | -$3 | -100 | -0.1% |
|
|
GS
4
GTS Securities
New York
| $1.07K | -$3 | -100 | -0.2% |
|
|
5
UBS Group
Zurich,
Switzerland
| $105 | -$69 | -2,000 | -32% |
|
|
WAM
6
Wolverine Asset Management
Chicago,
Illinois
| $47 | – | – | – |
|
|
NA
7
NewEdge Advisors
New Orleans,
Louisiana
| – | -$33 | -1,072 | Closed |
|
|
8
Bank of America
Charlotte,
North Carolina
| – | -$3 | -100 | Closed |
|
SABSW Hedge Fund Activity: Q1 2026 in Review
6 of the 8,150 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics Warrant (SABSW) for Q1 2026, worth a combined $21.1K — up 152% from $8.34K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of SABSW and 1 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 0 added.
The largest buyer was LMR Partners, opening a new position worth an estimated $18.6K. The largest seller was UBS Group, cutting an estimated $69.
- 6 institutional investors held SAB Biotherapeutics Warrant (SABSW) as of Q1 2026, down from 7 in Q4 2025.
- Funds reported $21.1K of SAB Biotherapeutics Warrant stock for Q1 2026, up 152% quarter-over-quarter.
- 1 fund opened new SAB Biotherapeutics Warrant positions in Q1 2026 and 2 closed out, a net change of -1 holder.
- The largest SAB Biotherapeutics Warrant buyer in Q1 2026 was LMR Partners, an estimated $18.6K added.
- The largest SAB Biotherapeutics Warrant seller in Q1 2026 was UBS Group, an estimated $69 sold.
Based on aggregated 13F filings for Q1 2026.